Appleseed said...
I was hoping for you to stay @ a 0 for 2 years or more. I guess that’s asking too much..
I was hoping for the same. Being a sample of one and being in the standard treatment arm, there is no telling how typical my results thus far may be. It's possible, and I hope it is, that patients in the other two arms of the trial will have longer times to rising PSA and/or longer times to becoming hormone refractory, which is pretty much what this trial is trying to discover.
Thanks to the Titan, Arches, and Latitude trials we now know that Apalutamide, Enzalutamide, and Abiraterone Acetate have all been shown to be significantly beneficial when used earlier in patients who are still hormone sensitive and now have FDA approval for earlier use. But all the patients enrolled in those trials were required to have identified distant bone or soft tissue mets. Patients with no identified mets or with only local lymph node mets were excluded from those trials. With luck this Androgen Annihilation trial will show similar results for these meds when used even earlier in treatment.
Let us know how your randomization works out. Best.
Jim